Ind-Swift Laboratories Limited has submitted a Nil Statement on Deviation or Variation of Funds Raised through Preferential Issue of Convertible Warrants for the quarter ended December 31, 2025. The company confirms that there has been no deviation in the utilization of funds raised via preferential issue. The preferential issue of convertible warrants was undertaken on August 30, 2024, with a total issue size of ₹314.60 Crores. Out of this, ₹209.41 Crores has been raised and utilized during the quarter. The funds were raised for specific objects including Expansion of Business (₹150.00 Crores), Investment in existing or to be acquired Subsidiaries (₹50.00 Crores), Working Capital for existing business (₹39.60 Crores), and General Corporate Purpose (₹75.00 Crores). The total utilization for these objects as of December 31, 2025, was ₹208.95 Crores. The statement, reviewed by the Audit Committee, confirms no deviation from the originally disclosed utilization plans. A sum of ₹0.08 Crores is included in the utilized amount, representing an excess received from an allottee who did not exercise their right to convert warrants into equity.
